Ann Dermatol.  2015 Aug;27(4):371-375. 10.5021/ad.2015.27.4.371.

Efficacy and Safety of Calcipotriol/Betamethasone Dipropionate Ointment for the Treatment of Trachyonychia: An Open-Label Study

• Park JM
• Cho HH
• Kim WJ
• Mun JH
• Song M
• Kim HS
• Ko HC
• Kim BS
• Kim MB

• KMID: 2171491
• DOI: http://doi.org/10.5021/ad.2015.27.4.371

Abstract

BACKGROUND
Despite efforts to treat trachyonychia, there is no promising treatment modality.
OBJECTIVE
This study evaluated the efficacy and safety of calcipotriol plus betamethasone dipropionate ointment on trachyonychia.
METHODS
A total of 39 patients with 432 nails affected by trachyonychia were enrolled. All patients applied calcipotriol/betamethasone ointment once daily without occlusion for 6 months. Outcome measures were assessed by physician's global assessment (degree of roughness: 0, clear; 1, mild; 2, moderate; 3, marked; 4, severe) at all time points.
RESULTS
After 6 months of therapy, 98.6% (426/432) of nails showed significant clinical improvement; 4.2% were completely free from nail lesions. The mean physician global assessment score decreased significantly from 3.5 to 1.7 points (p< 0.05). No serious side effects were reported, except mild pruritus and erythema in 2 patients.
CONCLUSION
This is the first study to prospectively evaluate the efficacy and safety of calcipotriol/betamethasone ointment for the treatment of trachyonychia. The results indicate topical calcipotriol/betamethasone is an effective and safe treatment for symptom improvement of trachyonychia.

Keyword

Calcipotriol/betamethasone; Nails; Psoriasis; Topical; Trachyonychia; Treatment

MeSH Terms

Betamethasone
Erythema
Humans
Outcome Assessment (Health Care)
Prospective Studies
Pruritus
Psoriasis
Betamethasone

Figure

• 

  Fig. 1 Severity index of trachyonychia: (A) stage 0, (B) stage I, (C) stage II, (D) stage III, (E) stage IV.

• 

  Fig. 2 Temporal changes of mean physician global assessment (PGA) score (*p<0.05 vs. baseline).

• 

  Fig. 3 Temporal changes of physician global assessment score (n=432 nails).

• 

  Fig. 4 Temporal changes of trachyonychia after calcipotriol/betamethasone dipropionate ointment.

Reference

1. Gordon KA, Vega JM, Tosti A. Trachyonychia: a comprehensive review. Indian J Dermatol Venereol Leprol. 2011; 77:640–645.

2. Sakata S, Howard A, Tosti A, Sinclair R. Follow up of 12 patients with trachyonychia. Australas J Dermatol. 2006; 47:166–168.

3. Peloro TM, Pride HB. Twenty-nail dystrophy and vitiligo: a rare association. J Am Acad Dermatol. 1999; 40:488–490.

4. Khandpur S, Reddy BS. An association of twenty-nail dystrophy with vitiligo. J Dermatol. 2001; 28:38–42.

5. Khandpur S, Bansal A, Sharma VK, Bhatti SS, Singh MK. Twenty nail dystrophy in vitiligo. J Dermatol. 2007; 34:189–192.

6. Scardamaglia L, Howard A, Sinclair R. Twenty-nail dystrophy in a girl with incontinentia pigmenti. Australas J Dermatol. 2003; 44:71–73.

7. Sehgal VN. Twenty nail dystrophy trachyonychia: an overview. J Dermatol. 2007; 34:361–366.

8. Soda R, Diluvio L, Bianchi L, Chimenti S. Treatment of trachyonychia with tazarotene. Clin Exp Dermatol. 2005; 30:301–302.

9. Schissel DJ, Elston DM. Topical 5-fluorouracil treatment for psoriatic trachyonychia. Cutis. 1998; 62:27–28.

10. Halkier-Sørensen L, Cramers M, Kragballe K. Twenty-nail dystrophy treated with topical PUVA. Acta Derm Venereol. 1990; 70:510–511.

11. Khoo BP, Giam YC. A pilot study on the role of intralesional triamcinolone acetonide in the treatment of pitted nails in children. Singapore Med J. 2000; 41:66–68.

12. Tosti A, Piraccini BM, Cambiaghi S, Jorizzo M. Nail lichen planus in children: clinical features, response to treatment, and long-term follow-up. Arch Dermatol. 2001; 137:1027–1032.

13. Brazzelli V, Martinoli S, Prestinari F, Borroni G. An impressive therapeutic result of nail psoriasis to acitretin. J Eur Acad Dermatol Venereol. 2004; 18:229–230.

14. Piérard GE, Piérard-Franchimont C. Dynamics of psoriatic trachyonychia during low-dose cyclosporin A treatment: a pilot study on onychochronobiology using optical profilometry. Dermatology. 1996; 192:116–119.

15. Park JY, Rim JH, Choe YB, Youn JI. Comparison of calcipotriol monotherapy and a combination of calcipotriol and methylprednisolone aceponate therapy in psoriasis patients. Ann Dermatol. 2003; 15:60–63.

16. Rigopoulos D, Gregoriou S, Daniel Iii CR, Belyayeva H, Larios G, Verra P, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009; 218:338–341.

17. Baran R, Dawber RPR, Richert B. Physical signs. In : Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti A, editors. Diseases of the nails and their management. 3rd ed. Oxford: Blackwell Science;2001. p. 67–69.

18. Tosti A, Bardazzi F, Piraccini BM, Fanti PA. Idiopathic trachyonychia (twenty-nail dystrophy): a pathological study of 23 patients. Br J Dermatol. 1994; 131:866–872.

19. Grover C, Khandpur S, Reddy BS, Chaturvedi KU. Longitudinal nail biopsy: utility in 20-nail dystrophy. Dermatol Surg. 2003; 29:1125–1129.

20. Theng CT, Tan SH, Goh CL, Suresh S, Wong HB, Machin D. Singapore Lichen Planus Study Group. A randomized controlled trial to compare calcipotriol with betamethasone valerate for the treatment of cutaneous lichen planus. J Dermatolog Treat. 2004; 15:141–145.

21. Basak PY, Ergin S. Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp. J Eur Acad Dermatol Venereol. 2001; 15:86–88.

22. Wolf R, Tur E, Brenner S. Corticosteroid-induced disappearing digit. J Am Acad Dermatol. 1990; 23:755–756.

23. Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol. 1997; 37:S55–S58.